Point72 DIFC Ltd Purchases Shares of 12,284 Cardiff Oncology, Inc. (NASDAQ:CRDF)

Point72 DIFC Ltd purchased a new stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 12,284 shares of the company’s stock, valued at approximately $27,000.

Several other institutional investors have also added to or reduced their stakes in the business. Dimensional Fund Advisors LP boosted its position in Cardiff Oncology by 34.4% during the second quarter. Dimensional Fund Advisors LP now owns 19,098 shares of the company’s stock valued at $42,000 after buying an additional 4,892 shares during the period. Vanguard Group Inc. boosted its position in Cardiff Oncology by 0.5% during the first quarter. Vanguard Group Inc. now owns 1,921,257 shares of the company’s stock valued at $10,260,000 after buying an additional 9,468 shares during the period. Callan Capital LLC boosted its position in Cardiff Oncology by 37.2% during the first quarter. Callan Capital LLC now owns 42,747 shares of the company’s stock valued at $228,000 after buying an additional 11,600 shares during the period. Ground Swell Capital LLC purchased a new stake in Cardiff Oncology during the second quarter valued at about $38,000. Finally, American Century Companies Inc. boosted its position in Cardiff Oncology by 98.7% during the second quarter. American Century Companies Inc. now owns 45,360 shares of the company’s stock valued at $101,000 after buying an additional 22,536 shares during the period. 16.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Craig Hallum assumed coverage on shares of Cardiff Oncology in a research report on Friday, September 6th. They set a “buy” rating and a $8.00 price target for the company.

Cardiff Oncology Trading Up 0.4 %

Cardiff Oncology stock opened at $2.77 on Monday. The firm has a 50-day moving average of $2.37 and a 200-day moving average of $3.24. The firm has a market cap of $123.89 million, a P/E ratio of -3.08 and a beta of 1.95. Cardiff Oncology, Inc. has a 1-year low of $0.94 and a 1-year high of $6.42.

Cardiff Oncology (NASDAQ:CRDF) last posted its earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). The firm had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.12 million. Cardiff Oncology had a negative return on equity of 62.65% and a negative net margin of 6,143.91%. During the same quarter in the prior year, the company posted ($0.25) earnings per share. Research analysts forecast that Cardiff Oncology, Inc. will post -1 earnings per share for the current fiscal year.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.